ComKardia Announces Expansion of Leadership Team with Renowned Global Cardiovascular Innovators
Miami, Florida — December 8, 2025 — ComKardia, a leader in next-generation cardiovascular intelligence and AI-enabled precision intervention, today announced a significant expansion of its leadership and advisory team with the appointment of three globally distinguished medical innovators. These leaders bring unparalleled expertise in cardiovascular medicine, translational science, clinical research, and health-system strategy further strengthening ComKardia’s mission to transform cardiovascular care worldwide.
Dr. Pascal Goldschmidt Appointed Chairman of the Advisory Board
ComKardia is honored to welcome Dr. Pascal J. Goldschmidt, an internationally recognized cardiologist, academic executive, and healthcare innovator, as Chairman of the Advisory Board.
Dr. Goldschmidt previously served as:
• Dean, University of Miami Leonard M. Miller School of Medicine
• CEO, University of Miami Health System (UHealth)
• Senior Cardiovascular Research Leader at Duke University and Johns Hopkins University
A pioneering force in cardiovascular discovery, institutional transformation, and digital innovation, Dr. Goldschmidt brings decades of leadership in developing breakthrough technologies and advancing global standards of care. His strategic guidance will help accelerate ComKardia’s development of advanced, clinically integrated platforms that empower cardiologists with real-time decision support.
Dr. William O’Neill Joins as Advisory Board Member
ComKardia also welcomes Dr. William O’Neill, one of the world’s most influential interventional cardiologists, as Member of the Advisory Board.
Dr. O’Neill is widely recognized as:
• A pioneer of transcatheter cardiovascular therapies
• A global authority on cardiogenic shock management
• A leading voice in structural heart innovation and complex PCI
His decades of clinical leadership and hands-on innovation will play a pivotal role in guiding ComKardia’s product roadmap, clinical trial strategy, and deployment within major cardiovascular centers.
Dr. David Kandzari Appointed to Advisory Board
ComKardia further welcomes Dr. David Kandzari, one of the nation’s foremost clinician-scientists in coronary and endovascular interventions, as Advisory Board Member.
Dr. Kandzari currently serves as:
• Chief of Cardiovascular Medicine, Piedmont Heart Institute
• Director, Interventional Cardiology, Piedmont Heart Institute
He has led numerous landmark global clinical trials and is internationally known for advancing coronary stent technologies, renal denervation, and evidence-based interventional therapy. His expertise will support ComKardia’s strategic clinical validation, regulatory advancement, and broad clinical adoption.
Strengthening ComKardia’s Mission
“These leaders represent the highest echelon of cardiovascular medicine,” said Maria Kyparissopoulou, CEO of ComKardia. “Their collective expertise accelerates our mission to bring AI-powered cardiovascular decision support to clinicians everywhere—reducing variability, improving outcomes, and transforming how interventional cardiology is practiced globally.”
About ComKardia
ComKardia is a precision-cardiology technology company developing AI-enabled digital-twin platforms that support interventional cardiologists before, during, and after percutaneous coronary interventions (PCI). By combining advanced computational modeling, real-time analytics, and clinician-centered design, ComKardia aims to improve outcomes, optimize workflow, and elevate the standard of cardiovascular care worldwide.
Contact
Maria Kyparissopoulou
Email: maria.kyparissopoulou@comkardia.com
Phone: 857.234.2646